// App-Quantinova.ai

TPS5091 : Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.

Researchers

Presenter

  • Neeraj Agarwal

Principal Investigators

  • Arun Azad

  • Andre Fay

  • Joan Carles

  • Neal D. Shore

  • Luke T. Nordquist

  • Lawrence Ivan Karsh

  • Curtis Dunshee

  • Srinand Ponnathapura Nandakumar

  • Beth Sullivan

  • Akos Czibere

  • Fong Wang

  • Karim Fizazi

Medical Centers

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Deakin University, Melbourne, Australia

  • PUCRS School of Medicine, Porto Alegre, Brazil

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • GU Research Network, LLC, Omaha, NE

  • The Urology Center of Colorado, Denver, CO

  • Urological Associates of Southern Arizona, Tucson, AZ

  • Amgen Inc, South San Francisco, CA

  • Pfizer, Groton, CT

  • Pfizer Inc., Cambridge, MA

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • Brazil

  • Spain

  • Australia

  • United States

  • France

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Enzalutamide

  • Mitoxantrone

  • Talazoparib

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT03395197

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved